Management of Left Ventricular Non-Compaction
Manage left ventricular non-compaction based on the degree of LV systolic dysfunction and presence of sustained ventricular arrhythmias using the same criteria as dilated cardiomyopathy, rather than treating the trabeculation pattern itself as an independent indication for intervention. 1
Core Management Principles
The fundamental approach recognizes that LV non-compaction by itself is NOT an indication for aggressive interventions like ICD placement 1. Instead, management targets the clinical manifestations and complications that may accompany this morphologic pattern.
Heart Failure Management
- Treat symptomatic heart failure with standard guideline-directed medical therapy including diuretics for volume management 1
- Optimize heart rate control to improve LV filling, particularly important given the trabeculated myocardium 1
- Apply the same neurohormonal antagonist strategies used in dilated cardiomyopathy (ACE inhibitors/ARBs, beta-blockers, mineralocorticoid receptor antagonists) when systolic dysfunction is present 2
Thromboembolism Prevention
Anticoagulation is mandatory in all patients with atrial fibrillation (paroxysmal, persistent, or permanent) 1
Consider anticoagulation for patients with LV non-compaction who have:
- Documented LV thrombus 3
- Severely reduced ejection fraction with blood stasis in deep intertrabecular recesses 3
- History of prior thromboembolic events 1
The rationale is that blood stasis within prominent trabeculations and deep recesses creates a substrate for thrombus formation, with reported cerebral embolism risk up to 24% in some series 3.
Sudden Cardiac Death Risk Stratification
ICD decisions must be guided by LV systolic dysfunction severity and sustained ventricular arrhythmias, NOT by the presence of trabeculation alone 1
ICD should be considered when:
- LVEF <40% with symptomatic heart failure (using dilated cardiomyopathy criteria) 1
- Sustained ventricular arrhythmias causing hemodynamic instability in patients expected to survive >1 year with good functional status 1
- History of aborted sudden cardiac death or hemodynamically destabilizing ventricular tachycardia 2
Risk factors predicting increased mortality include:
- Increased age at presentation 1
- Larger LV end-diastolic diameter 1
- Symptomatic heart failure 1
- Permanent or persistent atrial fibrillation 1
- Bundle branch block 1
- Associated neuromuscular disease 1
Family Screening and Genetic Evaluation
Screen first-degree relatives given that 18-50% of isolated LV non-compaction cases are familial with predominantly autosomal dominant inheritance 1, 4
Genetic testing should be pursued as mutations in sarcomeric proteins, calcium-handling proteins, and cardiomyopathy-related genes (LMNA, LDB3, Taffazin, ZASP, TAZ/G4.5) have been identified 1, 4
Patients with identified mutations are at higher risk for major adverse cardiovascular events, particularly when combined with LV systolic dysfunction 4
Activity Restrictions
Asymptomatic athletes with LV non-compaction and preserved systolic function may selectively participate in competitive sports if they meet ALL of the following criteria 5:
- No history of unexplained syncope
- No frequent or complex ventricular arrhythmias on ambulatory monitoring and exercise testing
- Normal or near-normal LV ejection fraction
Athletes should be excluded from competitive sports if they have:
- Symptomatic heart failure 5
- LVEF <40% 5
- History of unexplained syncope 5
- Frequent/complex ventricular arrhythmias 5
Monitoring Strategy
Asymptomatic patients require regular surveillance including:
- Serial echocardiography or cardiac MRI to assess LV function and chamber dimensions 6, 7
- Ambulatory ECG monitoring to detect arrhythmias 1, 7
- Exercise testing to unmask exercise-induced arrhythmias 5, 7
Cardiac MRI provides superior assessment of trabeculation extent, compacted layer thickness, and presence of late gadolinium enhancement (which indicates fibrosis and worse prognosis) 6, 7
Critical Pitfalls to Avoid
Do not use the presence of trabeculation alone as justification for ICD implantation - there is insufficient evidence that LV non-compaction morphology by itself warrants primary prevention ICD 1
Recognize that current diagnostic criteria have poor specificity - 15-43% of asymptomatic individuals without cardiovascular disease may meet imaging criteria for non-compaction, suggesting this may represent an anatomical variant rather than true cardiomyopathy in many cases 6, 8
Distinguish between "hypertrabeculation phenotype" (excessive trabeculation) and true pathologic compact layer thinning - the latter represents the disease-specific mechanism accounting for systolic dysfunction 9, 10